A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
Public ClinicalTrials.gov record NCT05904886. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic HCC. Per amendment version 5, following a memo issued by the Sponsor, participants receiving treatment in the atezolizumab plus bevacizumab plus tiragolumab arm are recommended to discontinue tiragolumab treatment unless the investigator decides the benefit outweighs the risk. Participants receiving treatment in atezolizumab plus bevacizumab plus placebo arm must discontinue placebo treatment. Participants may continue receiving active treatment(s) per protocol until loss of clinical benefit or unacceptable toxicity, whichever occurs first.
Study identification
- NCT ID
- NCT05904886
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 687 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 13, 2023
- Primary completion
- May 7, 2025
- Completion
- Aug 31, 2026
- Last update posted
- Dec 30, 2025
2023 – 2026
United States locations
- U.S. sites
- 34
- U.S. states
- 18
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Genesis Cancer Center | Hot Springs | Arkansas | 71913 | — |
| UCSF Fresno at Community Cancer Institute | Clovis | California | 93611 | — |
| City of Hope Cancer Center | Duarte | California | 91010 | — |
| University of California San Diego Moores Cancer Center | La Jolla | California | 92037 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| Stanford Cancer Center | Palo Alto | California | 94304 | — |
| Va Palo Alto Health Care System | Palo Alto | California | 94304 | — |
| UCLA Cancer Center | Santa Monica | California | 90404 | — |
| Hartford Healthcare Cancer Institute at Hartford Hospital | Hartford | Connecticut | 06106 | — |
| MedStar Washington Hosp Center | Washington D.C. | District of Columbia | 20010 | — |
| Florida Cancer Specialists - Fort Myers (Broadway) | Fort Myers | Florida | 33901 | — |
| Miami VA Healthcare System | Miami | Florida | 33125 | — |
| Florida Cancer Specialist, North Region | St. Petersburg | Florida | 33705 | — |
| University of Illinois | Chicago | Illinois | 60612 | — |
| Norton Cancer Institute - Audubon | Louisville | Kentucky | 40217 | — |
| Ochsner Cancer Inst. | New Orleans | Louisiana | 70121 | — |
| Mercy Medical Center | Baltimore | Maryland | 21202 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Cancer & Hematology Centers of Western Michigan | Grand Rapids | Michigan | 49503 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Minnesota Oncology Hematology Woodbury | Woodbury | Minnesota | 55125 | — |
| Washington Uni School of Medicine | St Louis | Missouri | 63110 | — |
| NYU Langone | New York | New York | 10016 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Columbia University | New York | New York | 10032-3725 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| James J Peters VA Hospital / Mental Illness Research Education and Clinic Center | The Bronx | New York | 10468 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| Thomas Jefferson Uni | Philadelphia | Pennsylvania | 19107 | — |
| North Texas VA Medical Center | Dallas | Texas | 75216 | — |
| Kelsey Seybold Clnic | Houston | Texas | 77005 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| Swedish Cancer Inst. | Seattle | Washington | 98104 | — |
| Univ of Wisconsin-Madison | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 137 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05904886, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 30, 2025 · Synced Sep 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05904886 live on ClinicalTrials.gov.